Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 304, Issue 11, 2013, Pages

  Fischer, Andreas ^a   Gluth, Markus ^a   Pape, Ulrich Frank ^a   Wiedenmann, Bertram ^a   Theuring, Franz ^a   Baumgart, Daniel C ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Claudin; Crohn's disease; IBD; Intestinal barrier; Tumor necrosis factor ; Ulcerative colitis

Indexed keywords

ADALIMUMAB; CLAUDIN 1; CLAUDIN 2; CLAUDIN 4; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN LIGHT CHAIN; OCCLUDIN; PHOSPHATIDYLINOSITOL 3 KINASE; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CLAUDIN; CROHN'S DISEASE; IBD; INTESTINAL BARRIER; TUMOR NECROSIS FACTOR-Α; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CACO-2 CELLS; CYTOKINES; ELECTRIC IMPEDANCE; HUMANS; INTERFERON-GAMMA; INTESTINAL MUCOSA; MYOSINS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERMEABILITY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIGHT JUNCTION PROTEINS; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878667737     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00183.2012     Document Type: Article

References (54)

1. Amasheh M, Fromm A, Krug SM, Amasheh S, Andres S, Zeitz M, Fromm M, Schulzke JD. TNFα-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFκB signaling. J Cell Sci 123: 4145-4155, 2010.
2. Amasheh S, Fromm M, Gunzel D. Claudins of intestine and nephron-a correlation of molecular tight junction structure and barrier function. Acta Physiol (Oxf) 201: 133-140, 2011.
3. Angelow S, Yu AS. Claudins and paracellular transport: an update. Curr Opin Nephrol Hypertens 16: 459-464, 2007.
4. +) macrophages. Gastroenterology 141: 2026-2038, 2011.
5. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315, 2007.
6. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305: 1460-1468, 2011.
7. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640, 2007.
8. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657, 2007.
9. Boivin MA, Roy PK, Bradley A, Kennedy JC, Rihani T, Ma TY. Mechanism of interferon-gamma-induced increase in T84 intestinal epithelial tight junction. J Interferon Cytokine Res 29: 45-54, 2009.
10. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171: 6164-6172, 2003.
11. Bruewer M, Samarin S, Nusrat A. Inflammatory bowel disease and the apical junctional complex. Ann NY Acad Sci 1072: 242-252, 2006.
12. Capaldo CT, Nusrat A. Cytokine regulation of tight junctions. Biochim Biophys Acta 1788: 864-871, 2009.
13. Coskun M, Troelsen JT, Nielsen OH. The role of CDX2 in intestinal homeostasis and inflammation. Biochim Biophys Acta 1812: 283-289, 2011.
14. Costantini TW, Peterson CY, Kroll L, Loomis WH, Eliceiri BP, Baird A, Bansal V, Coimbra R. Role of p38 MAPK in burn-induced intestinal barrier breakdown. J Surg Res 156: 64-69, 2009.
15. Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, Neff J, Washington MK, Beauchamp RD. Claudin-1 regulates cellular transfor-mation and metastatic behavior in colon cancer. J Clin Invest 115: 1765-1776, 2005.
16. Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation. Adv Drug Deliv Rev 57: 883-917, 2005.
17. Fish SM, Proujansky R, Reenstra WW. Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function. Gut 45: 191-198, 1999.
18. Fries W, Muja C, Crisafulli C, Cuzzocrea S, Mazzon E. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. Am J Physiol Gastrointest Liver Physiol 294: G938-G947, 2008.
19. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323-333, 2006.
20. Hollander D. Crohn's disease, TNF-α, and the leaky gut. The chicken or the egg? Am J Gastroenterol 97: 1867-1868, 2002.
21. Ivanov AI, Parkos CA, Nusrat A. Cytoskeletal regulation of epithelial barrier function during inflammation. Am J Pathol 177: 512-524, 2010.
22. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, Said HM. TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation. Am J Physiol Gastrointest Liver Physiol 286: G367-G376, 2004.
23. Mankertz J, Amasheh M, Krug SM, Fromm A, Amasheh S, Hillenbrand B, Tavalali S, Fromm M, Schulzke JD. TNFα up-regulates claudin-2 expression in epithelial HT-29/B6 cells via phosphatidylinositol-3-kinase signaling. Cell Tissue Res 336: 67-77, 2009.
24. Marchiando AM, Shen L, Graham WV, Edelblum KL, Duckworth CA, Guan Y, Montrose MH, Turner JR, Watson AJ. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology 140: 1208-1218, 2011.
25. Marchiando AM, Shen L, Graham WV, Weber CR, Schwarz BT, Austin JR, Raleigh DR, Guan Y, Watson AJ, Montrose MH, Turner JR. Caveolin-1-dependent occludin endocytosis is required for TNFinduced tight junction regulation in vivo. J Cell Biol 189: 111-126, 2010.
26. Mees ST, Mennigen R, Spieker T, Rijcken E, Senninger N, Haier J, Bruewer M. Expression of tight and adherens junction proteins in ulcerative colitis associated colorectal carcinoma: up regulation of claudin-1, claudin-3, claudin-4, and β-catenin. Int J Colorectal Dis 24: 361-368, 2009.
27. Noth R, Stuber E, Hasler R, Nikolaus S, Kuhbacher T, Hampe J, Bewig B, Schreiber S, Arlt A. Anti-TNF-alpha antibodies improve intestinal barrier function in Crohn's disease. J Crohns Colitis 6: 464-469, 2012.
28. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serinethreonine kinase. Nature 401: 82-85, 1999.
29. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panes J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, Van AG, Vecchi M, Mary JY, Colombel JF, Lemann M. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 17: 1415-1422, 2011.
30. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139: 1619-1625, 2009.
31. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
32. Poritz LS, Harris LR, III, Kelly AA, Koltun WA. Increase in the tight junction protein claudin-1 in Intestinal Inflammation. Dig Dis Sci 2011.
33. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, Macdonald TT, Collins JE. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 2005.
34. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60: 780-787, 2011.
35. Repetto G, del PA, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 3: 1125-1131, 2008.
36. Rutgeerts P, Van AG, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126: 1593-1610, 2004.
37. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, Chino A, Doi T, Saiki I. Tumor necrosis factor-β-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 278: 36916-36923, 2003.
38. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088-1094, 2001.
39. Schägger H. Tricine-SDS-PAGE. Nat Protoc 1: 16-22, 2006.
40. Scharl M, Paul G, Barrett KE, McCole DF. AMP-activated protein kinase mediates the interferon-γ-induced decrease in intestinal epithelial barrier function. J Biol Chem 284: 27952-27963, 2009.
41. Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, Richter J, Bojarski C, Schumann M, Fromm M. Epithelial tight junctions in intestinal inflammation. Ann NY Acad Sci 1165: 294-300, 2009.
42. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21: 251-258, 2005.
43. Shen L, Turner JR. Actin depolymerization disrupts tight junctions via caveolae-mediated endocytosis. Mol Biol Cell 16: 3919-3936, 2005.
44. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 73: 283-309, 2011.
45. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van AG, Geboes K, Ceuppens JL, Rutgeerts P. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97: 2000-2004, 2002.
46. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799-809, 2009.
47. Wajant H, Scheurich P. TNFR1-induced activation of the classical NF-κB pathway. FEBS J 278: 862-876, 2011.
48. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-γ and tumor necrosis factor-β synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 166: 409-419, 2005.
49. Wang F, Schwarz BT, Graham WV, Wang Y, Su L, Clayburgh DR, Abraham C, Turner JR. IFN-γ-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology 131: 1153-1163, 2006.
50. Wang Q, Guo XL, Wells-Byrum D, Noel G, Pritts TA, Ogle CK. Cytokine-induced epithelial permeability changes are regulated by the activation of the p38 mitogen-activated protein kinase pathway in cultured Caco-2 cells. Shock 29: 531-537, 2008.
51. Weber CR, Nalle SC, Tretiakova M, Rubin DT, Turner JR. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest 88: 1110-1120, 2008.
52. Weber CR, Raleigh DR, Su L, Shen L, Sullivan EA, Wang Y, Turner JR. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem 2010.
53. Zeissig S, Burgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M, Schulzke JD. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56: 61-72, 2007.
54. Zimny-Arndt U, Schmid M, Ackermann R, Jungblut PR. Classical proteomics: two-dimensional electrophoresis/MALDI mass spectrometry. Methods Mol Biol 492: 65-91, 2009.